Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin PK/PD in Japanese T1DM
NCT02582840Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of dapagliflozin in type 1 diabetes mellitus (T1D) (3 arms), sponsored by AstraZeneca. Primary endpoints: Dapagliflozin Maximum Observed Plasma Concentration, Dapagliflozin Minimum Observed Plasma Concentration and 5 more. Started Oct 2015; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02582840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582840.